128 related articles for article (PubMed ID: 29088716)
1. Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation.
Fisher ML; Ciavattone N; Grun D; Adhikary G; Eckert RL
Oncotarget; 2017 Sep; 8(43):73407-73418. PubMed ID: 29088716
[TBL] [Abstract][Full Text] [Related]
2. NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.
Grun D; Adhikary G; Eckert RL
Oncogene; 2018 Aug; 37(34):4711-4722. PubMed ID: 29755126
[TBL] [Abstract][Full Text] [Related]
3. VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype.
Mickle M; Adhikary G; Shrestha S; Xu W; Eckert RL
Mol Carcinog; 2021 Jul; 60(7):497-507. PubMed ID: 34004031
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.
Fisher ML; Grun D; Adhikary G; Xu W; Eckert RL
Oncotarget; 2017 Dec; 8(66):110257-110272. PubMed ID: 29299145
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.
Chen X; Adhikary G; Ma E; Newland JJ; Naselsky W; Xu W; Eckert RL
Mol Carcinog; 2023 Feb; 62(2):236-248. PubMed ID: 36285644
[TBL] [Abstract][Full Text] [Related]
6. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
[TBL] [Abstract][Full Text] [Related]
7. Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.
García P; Rosa L; Vargas S; Weber H; Espinoza JA; Suárez F; Romero-Calvo I; Elgueta N; Rivera V; Nervi B; Obreque J; Leal P; Viñuela E; Aguayo G; Muñiz S; Sagredo A; Roa JC; Bizama C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218280
[TBL] [Abstract][Full Text] [Related]
8. Targeting loss of the Hippo signaling pathway in
Sourbier C; Liao PJ; Ricketts CJ; Wei D; Yang Y; Baranes SM; Gibbs BK; Ohanjanian L; Spencer Krane L; Scroggins BT; Keith Killian J; Wei MH; Kijima T; Meltzer PS; Citrin DE; Neckers L; Vocke CD; Marston Linehan W
Oncotarget; 2018 Feb; 9(12):10723-10733. PubMed ID: 29535838
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.
Shigeeda W; Shibazaki M; Yasuhira S; Masuda T; Tanita T; Kaneko Y; Sato T; Sekido Y; Maesawa C
Oncotarget; 2017 Nov; 8(55):93729-93740. PubMed ID: 29212185
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
12. An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers.
Lan C; Ni B; Zhao T; Li Z; Wang J; Ma Y; Li W; Wang X
Front Genet; 2022; 13():866702. PubMed ID: 35685435
[No Abstract] [Full Text] [Related]
13. The Hippo signaling pathway provides novel anti-cancer drug targets.
Bae JS; Kim SM; Lee H
Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075
[TBL] [Abstract][Full Text] [Related]
14. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.
Mi W; Lin Q; Childress C; Sudol M; Robishaw J; Berlot CH; Shabahang M; Yang W
Oncogene; 2015 Jun; 34(24):3095-106. PubMed ID: 25109332
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane suppresses oral cancer cell migration by regulating cathepsin S expression.
Chen CT; Hsieh MJ; Hsieh YH; Hsin MC; Chuang YT; Yang SF; Yang JS; Lin CW
Oncotarget; 2018 Apr; 9(25):17564-17575. PubMed ID: 29707130
[TBL] [Abstract][Full Text] [Related]
16. Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers.
Cottini F; Anderson KC; Tonon G
Mol Cell Oncol; 2014; 1(3):e970055. PubMed ID: 27308358
[TBL] [Abstract][Full Text] [Related]
17. Correction to: Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Carcinogenesis; 2023 Oct; 44(7):626-627. PubMed ID: 37549132
[No Abstract] [Full Text] [Related]
18. Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance.
Harada K; Song S; Ajani JA
Oncoscience; 2018 Jul; 5(7-8):214-215. PubMed ID: 30234141
[No Abstract] [Full Text] [Related]
19. Correction to: YAP1 acts as a negative regulator of pro-tumor TAZ expression in esophageal squamous cell carcinoma.
Kuo YZ; Kang YR; Chang WL; Sim LCL; Hsieh TC; Chang CH; Wang YC; Tsai CJ; Huang LC; Tsai ST; Wu LW
Cell Oncol (Dordr); 2022 Oct; 45(5):911. PubMed ID: 36223034
[No Abstract] [Full Text] [Related]
20. Corrigendum to "The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer" [Canc. Lett. 423 (2018) 36-46].
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Sep; 431():244. PubMed ID: 29754994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
